Table 2.
Pregnancies details with maternal characteristic and neonatal outcomes.
| Pregnancy ID | Pregnancy from Study | Indication for Treatment |
Treatment | Doses | Exposure Time | Mode of Delivery | GA at Delivery (Weeks) | Birth Weight (g) | Obstetric Complication | Child Sex | Child Wellbeing |
Breasfeeding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 14 | HLH | Anakinra | 200 mg/ twice daily |
22 w–B | C- section |
NA | NA | None | NA | Anaemia and bone marrow suppression | NA |
| 2 | 19 | FMF + amyloidosis | Canakinumab | 150 mg/6 weeks | PC–8 w | NA | Term | NA | None | NA | Healthy | NA |
| 3 | 19 | FMF | Canakinumab | 150 mg/8 weeks | PC–PPT | NA | NA | NA | NA | NA | NA | NA |
| 4 * | 7 | Chronic inflammatory rheumatic disease | Anakinra | NA | NA | Vaginal | NA | NA | Voluntary abortion | NA | NA | NA |
| 5 | 1 | AOSD | Anakinra | 100 mg/ day |
PC–B | Vaginal | 40.7 | 2700 | Placental retention requiring manual abruption |
F | Healthy | Yes |
| 6 | 4 | FCAS | Anakinra | 100 mg/ day |
PC–B | Vaginal | 41.0 | 3742 | None | NA | Healthy | No |
| 7 | 4 | FCAS | Anakinra | 100 mg/ day |
PC–B | Vaginal | 41.0 | 3629 | None | NA | FCAS | No |
| 8 | 4 | FCAS | Anakinra | 100 mg/ day |
PC–B | Vaginal | 38.0 | 3402 | None | NA | FCAS | Yes |
| 9 | 4 | FCAS | Anakinra | 100 mg/ day |
PC–B | Vaginal | 37.0 | 3459 | None | NA | Healthy | No |
| 10 | 4 | FCAS | Anakinra | 100 mg/ day |
PC–B | Vaginal | 37.7 | 2977 | None | NA | FCAS | No |
| 11 | 4 | FCAS | Anakinra | 100 mg/ day |
PC–B | Vaginal | 39.0 | 3345 | None | NA | Healthy | No |
| 12 | 4 | NOMID | Anakinra | 300 mg/ day |
PC–B | C- section |
40.0 | 4139 | Chronic hypertension |
NA | Healthy | Yes |
| 13 | 4 | NOMID | Anakinra | 239–300 mg/ day |
PC–B | Vaginal | A: 38.7 B: 30.0 |
A: 2637 B: NA |
A: None B: PTB |
NA | A: Healthy B: Renal agenesis (death) | A: Yes B: No |
| 14 | 4 | MWS/NOMID | Anakinra | 100 mg/ day |
PC–B | C- section |
Term | 3515 | None | NA | MWS | No |
| 15 | 15 | AOSD | Anakinra | NA | PC–B | C- section |
28.0 | 1175 | PTB | F | Healthy | NA |
| 16 | 15 | AOSD | Anakinra | NA | PC–B | Vaginal | 40.0 | 3480 | None | M | Healthy | NA |
| 17 | 15 | AOSD | Anakinra | NA | PC–B | Vaginal | 38.0 | 3450 | None | M | Healthy | NA |
| 19 | 12 | FMF | Anakinra | 100 mg/ day |
6 w–B | C- section |
Term | 3340 | None | F | Healthy | Yes |
| 20 | 17 | MWS | Canakinumab | 150 mg/ 8 weeks, then every 4–5 weeks |
PC–34 w | C- section |
39.0 | 2994 | None | F | Healthy with NLRP3 mutation |
NA |
| 22 | 11 | FMF | Anakinra | 100 mg/ day |
PC–29 w + 33 w–B | C- section |
38.0 | NA | Incision site infection in postpartum | M | Healthy | NA |
| 24 | 11 | FMF | Anakinra | NA | 16 w–B | C- section |
31.0 | NA | PTB | F-F twins | Healthy | NA |
| 25 | 11 | FMF | Anakinra | NA | 23 w–B | C- section |
37.0 | NA | NA | F | Healthy | NA |
| 26 | 11 | FMF | Anakinra | NA | 32 w–B | C- section |
40.0 | NA | NA | F | Healthy | NA |
| 27 | 11 | FMF | Anakinra | NA | PC–B with 1 month interruption | C- section |
38.0 | NA | NA | F | Healthy | NA |
| 28 | 11 | FMF | Anakinra | NA | 34 w–B | Vaginal | 37.0 | NA | Stillbirth | M | NA | |
| 29 | 11 | FMF | Anakinra | NA | 6 w–B | C- section |
36.0 | NA | PTB | F | Healthy | NA |
| 30 | 11 | FMF | Anakinra | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 31 * | 11 | FMF | Anakinra | NA | 5 w–8 w (ongoing) | NA | NA | NA | NA | NA | NA | NA |
| 32 * | 11 | FMF | Anakinra | NA | PC–8 w (ongoing) | NA | NA | NA | NA | NA | NA | NA |
| 33 | 2 | AOSD | Anakinra | 100 mg/ day |
PC–B | Vaginal | 39.0 | 3100 | None | M | Healthy | No |
| 34 | 2 | AOSD | Anakinra | NA | 12 w–B | C- section |
36.0 | 2800 | PTB | M | Healthy | No |
| 35 | 18 | sJIA | Canakinumab | NA | PC–35 w | Vaginal | 39.0 | NA | Forceps + minor episiotomy wound infection |
M | Healthy | NA |
| 36 | 21 | MWS | Canakinumab and Ana kinra | NA | PC–B | NA | NA | NA | NA | M | Healthy with CAPS | Yes |
| 37 | 8 | FMF | Anakinra | 100 mg/ day |
PC–B | C- section |
38.0 | 2700 | None | NA | Healthy | Yes |
| 38 * | 20 | CAPS | Anakinra | NA | PC–NA (ongoing) | NA | NA | NA | NA | NA | NA | NA |
| 39 * | 20 | CAPS | Canakinumab | NA | PC–8 w (ongoing) | NA | NA | NA | NA | NA | NA | NA |
| 40 | 20 | CAPS | Anakinra | NA | PC–B | Vaginal | NA | NA | None | M | Healthy | No |
| 41 | 20 | TRAPS | Anakinra | NA | PC–B | Vaginal | NA | NA | None | M | Unilateral reduced hearing at 6 weeks | No |
| 42 | 20 | FMF | Anakinra | 100 mg/ day |
21 w–B | C- section |
36.0 | NA | Vaginal bleeding, PTB | M | Healthy | Yes |
| 43 | 20 | idiopathic pericarditis | Anakinra | NA | PC–B | Vaginal | NA | NA | None | M | Healthy | No |
| 44 | 20 | AOSD | Anakinra | NA | 22 w–33 w | Vaginal | NA | NA | None | M | Healthy | No |
| 50 | 6 | FMF | Anakinra | 100 mg/ day |
12 w–B | Vaginal | 40.0 | NA | None | F | Healthy | Yes |
| 52 | 6 | FMF | Anakinra | NA | 15 w–B | Vaginal | 38.0 | NA | None | M | Low thrombocyte count treated by IVIG |
NA |
| 54 | 3 | sJIA | Anakinra | NA | P–B | NA | Term | NA | NA | NA | NA | NA |
| 55 | 13 | FMF | Anakinra | 100 mg/ day |
P–B | NA | NA | NA | None | NA | NA | NA |
| 56 | 9 | sJIA | Anakinra | 100 mg/ day |
PC–20.4 w | C- section |
37.1 | 2419 | Hypertension, oligohydramnios, breech presentation |
M | Jaundice, right hydrocele and heart murmur |
No |
| 57 | 9 | AOSD | Anakinra | 100 mg/ day |
20 w–38.1 w | Vaginal | 40.1 | 2940 | None | M | Jaundice | NA |
| 58 | 9 | AOSD | Anakinra | 100 mg/ day |
PC– 16.6 w + 19.4 w– 37.3 w |
C- section |
39.4 | 3632 | None | M | Jaundice | Yes |
| 59 | 9 | AOSD | Anakinra | 100 mg/ day |
PC– 2 w + 9.6 w– 36.7 w |
Vaginal | 38.7 | 3519 | None | M | Tongue-tied | Yes |
| 60 | 9 | sJIA | Anakinra | 100 mg/ day |
PC– 37.3 w |
Vaginal | 39.4 | 2640 | Oligohydramnios | F | Healthy | No |
| 61 | 10 | FMF | Anakinra | 100 mg/ day |
P–B | C- section |
40.6 | 4025 | None | NA | Healthy | Yes |
| 62 | 10 | FMF | Anakinra | 100 mg/ day |
2e trimester–B | C- section |
33.7 | 3320 | PTB | NA | Healthy, hypotrophic, respiratory distress syndrome, hyperbilirubinemia and poor drinking |
No |
| 63 | 10 | FMF | Anakinra | 100 mg/2 days | P–B | C- section |
39.3 | 4030 | Premature bleeding | NA | Healthy | NA |
| 64 | 10 | FMF | Anakinra | 100 mg/2 days | P–B | C- section |
36.4 | 3320 | PTB | NA | Healthy | NA |
| 66 | 16 | HLH | Anakinra | NA | 22 w–B | C- section |
31.7 | NA | PTB, IUGR, abnormal umbilical artery Doppler and subsequent cardiotocography was abnormal |
M | Neonatal unit briefly but healthy | NA |
| 67 | 22 | CAPS | Canakinumab | 150 mg/ 8 weeks |
PC–8 w | C- section |
38.0 | 3540 | Gestationnal diabetes | M | Healthy | No |
| 68 | 22 | CAPS | Canakinumab | 150 mg/ 8 weeks |
PC–12 w | Vaginal | 40.0 | 4480 | None | F | Healthy | Yes |
| 69 | 22 | CAPS | Canakinumab | 150 mg/ 8 weeks |
1 w–36 w | NA | 40.0 | 3570 | None | M | Healthy | NA |
| 70 | 22 | CAPS | Canakinumab | 120 mg (single dose) | P | NA | 38.0 | 3290 | None | M | Healthy | Yes |
| 71 | 22 | Un-SAID | Canakinumab | 300 mg/ 8 weeks |
PC–B | Vaginal | 39.0 | NA | None | M | Healthy | NA |
| 72 | 22 | FMF | Canakinumab | 150 mg/ 4 weeks |
PC–B | C- section |
37.0 | 3300 | None | M | Healthy | Yes |
| 73 | 22 | FMF | Canakinumab | 150 mg/ 8 weeks |
PC–4 w | C- section |
40.0 | 3300 | None | F | Healthy | Yes |
| 74 * | 22 | Cogan syndrome | Canakinumab | 150 mg/ 4 weeks |
PC–4 w | Vaginal | 4.0 | NA | Miscarriage | NA | NA | |
| 75 | 22 | CAPS | Anakinra | 50 mg/ day |
PC–B | Vaginal | 39.0 | 3940 | None | M | Healthy | No |
| 76 | 22 | CAPS | Anakinra | 50 mg/ day |
PC–B | Vaginal | 39.0 | NA | None | F | Healthy | No |
| 77 | 22 | CAPS | Anakinra | 100 mg/ day |
PC–B | Vaginal | 41.1 | 3600 | None | M | Healthy | Yes |
| 78 | 22 | CAPS | Anakinra | 100 mg/ day |
PPT–B | Vaginal | 40.0 | 4480 | None | F | Healthy | Yes |
| 79 | 22 | CAPS | Anakinra | 100 mg/ day |
36 w–B | NA | 40.0 | 3570 | None | M | Healthy | NA |
| 80 | 22 | CAPS | Anakinra | 100 mg/ day |
1 w–PPT | NA | 36.9 | 2830 | PTB | M | Healthy | No |
| 81 | 22 | CAPS | Anakinra | 100 mg/ day |
PC–B | C- section |
38.9 | NA | C-section due to failure to progress | NA | Healthy | NA |
| 82 | 22 | CAPS | Anakinra | 100 mg/ day |
PC–6 w | C- section |
40.0 | NA | None | M | Healthy | NA |
| 83 | 22 | CAPS | Anakinra | 100 mg/ day |
PC–B | NA | NA | NA | None | M | Healthy | Yes |
| 84 | 22 | CAPS | Anakinra | 100 mg/ day |
NA | NA | 40.1 | NA | None | F | Healthy | NA |
| 85 | 22 | CAPS | Anakinra | 100 mg/ day |
NA | NA | NA | NA | None | F | Healthy | NA |
| 86 | 22 | CAPS | Anakinra | 100 mg/ day |
NA | NA | NA | NA | None | F | Healthy | NA |
| 87 | 22 | FMF | Anakinra | 100 mg/ day |
PC–B | C- section |
36.1 | 2170 | Vaginal bleeding, PTB | M | Healthy | Yes |
| 88 | 22 | FMF | Anakinra | 100 mg/ day |
12 w–B | Vaginal | 40.0 | 3170 | None | F | Healthy | Yes |
| 89 | 22 | FMF | Anakinra | 100 mg/ day |
PC–B | Vaginal | 36.0 | 1600 | PTB | F | Healthy | Yes |
| 90 | 22 | idiopathic pericarditis | Anakinra | 100 mg/ day |
PC–PPT | Vaginal | 38.3 | 2930 | None | M | Healthy | No |
| 91 | 22 | AOSD | Anakinra | 200–300 mg/ day |
PC–16 w | NA | 37.0 | 2450 | None | F | Healthy | No |
| 92 | 22 | AOSD | Anakinra | 100 mg/ day |
22 w– 33 w |
NA | 35.1 | 2020 | PTB | M | Healthy | Yes |
| 93 | 22 | AOSD | Anakinra | 100 mg/ day |
9 w–B | C- section |
38.1 | NA | None | M | Left renal agenesis | Yes |
| 94 | 22 | AOSD | Anakinra | 100 mg/ day |
NA | Vaginal | 38.0 | 3060 | None | F | Healthy | Yes |
| 95 | 22 | TRAPS | Anakinra | 100 mg/ day |
PC–B | Vaginal | 41.0 | 3230 | None | M | Healthy | Yes |
| 96 | 22 | TRAPS | Anakinra | 100 mg/ day |
PC–B | NA | NA | NA | None | F | Healthy | NA |
HLH: hemophagocytic lymphohistiocytosis, FMF: familial mediterranean fever, AOSD: adult-onset Still’s disease, FCAS: familial cold autoinflammatory Syndrome, NOMID: neonatal-onset multisystem inflammatory disease, MWS: Muckle-Wells syndrome, sJIA: systemic juvenile idiopathic arthritis, CAPS: cryopyrin-associated autoinflammatory syndromes, NA: not available, PC: prior to conception, B: birth, PPT: pregnancy positive test, P: pregnancy, GA: gestational age, PTB: preterm birth, IUGR: intra-uterine growth restriction, M: male, F: female, *: Excluded from further analysis since data missing.